Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Pharmaust Limited ( (AU:NUZ) ) is now available.
Neurizon Therapeutics Limited announced a webinar to update shareholders on its Q3 FY2025 results and progress in advancing NUZ-001 for the HEALEY ALS Platform Trial. The presentation will cover regulatory engagements, industry participation, executive appointments, and future milestones, highlighting Neurizon’s commitment to developing treatments for neurodegenerative diseases and enhancing its industry positioning.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is advancing its lead drug candidate, NUZ-001, for ALS treatment and aims to accelerate access to effective therapies while exploring broader applications for neurodegenerative conditions.
YTD Price Performance: -21.11%
Average Trading Volume: 36,101
Technical Sentiment Signal: Buy
Current Market Cap: €39.32M
Find detailed analytics on NUZ stock on TipRanks’ Stock Analysis page.